Pfizer said it is working closely with its biotech partners to “ensure continuity and the successful transition of work.” (iStock/Getty Images Plus) As pharmas like Eli Lilly and Roche bolster their ...

Alongside a series A fundraise, OTR Therapeutics disclosed that it had acquired "a preclinical program with best-in-class potential for neurological diseases." (iStock / Getty Images Plus) Pfizer’s VC ...

Pfizer said it filed a second lawsuit against Novo Nordisk and Metsera, alleging that the Danish drugmaker's attempt to outbid Pfizer to acquire the obesity biotech is anticompetitive. The new suit ...

Pfizer said it has struck an up to $2.1 billion licensing deal with YaoPharma to develop and commercialize its obesity pill, furthering the pharma company's push into the weight loss space.

Meghana Keshavan covers biotech and contributes to The Readout newsletter. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

A proposal to crack down on China biotech dealmaking, a large Pfizer licensing deal and Astellas' roadmap made our news this week. (RomoloTavani/iStock/Getty Images ...

These players are vying for positions in the billion-dollar weight loss drug market. Demand for weight loss drugs is soaring, suggesting there's room for more than one winner. 10 stocks we like better ...

COPENHAGEN (Reuters) -Denmark's Novo Nordisk launched a rival bid for U.S. obesity biotech firm Metsera on Thursday, hijacking an offer from Pfizer as the drugmakers jostled for advantage in the ...